SG Americas Securities LLC Grows Stock Holdings in Penumbra, Inc. $PEN

SG Americas Securities LLC grew its stake in Penumbra, Inc. (NYSE:PEN) by 140.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,547 shares of the company’s stock after acquiring an additional 2,655 shares during the period. SG Americas Securities LLC’s holdings in Penumbra were worth $1,152,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of PEN. GAMMA Investing LLC boosted its holdings in shares of Penumbra by 7.3% in the second quarter. GAMMA Investing LLC now owns 761 shares of the company’s stock valued at $195,000 after purchasing an additional 52 shares during the period. Parkside Financial Bank & Trust raised its position in Penumbra by 70.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock valued at $41,000 after purchasing an additional 66 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Penumbra by 2.9% in the 2nd quarter. Quadrant Capital Group LLC now owns 2,872 shares of the company’s stock worth $737,000 after buying an additional 82 shares during the period. Corient Private Wealth LLC lifted its holdings in shares of Penumbra by 4.1% in the 2nd quarter. Corient Private Wealth LLC now owns 2,335 shares of the company’s stock worth $599,000 after buying an additional 92 shares during the period. Finally, Louisiana State Employees Retirement System grew its position in shares of Penumbra by 0.9% during the 2nd quarter. Louisiana State Employees Retirement System now owns 10,900 shares of the company’s stock worth $2,797,000 after buying an additional 100 shares in the last quarter. Institutional investors own 88.88% of the company’s stock.

More Penumbra News

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Boston Scientific agreed to acquire Penumbra for $374 per share in a cash-and-stock deal, citing strategic expansion into mechanical thrombectomy and neurovascular markets — the transaction creates a significant takeover premium that lifted investor interest. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Positive Sentiment: Penumbra issued preliminary Q4 and FY2025 results/guidance showing higher-than-consensus Q4 revenue guidance (~$383.0M–$384.8M vs. $361.9M consensus) and FY revenue around $1.4B — these operational beats support the deal valuation and the company’s growth profile. Penumbra provides preliminary update on Q4 and FY2025 results
• Neutral Sentiment: Wells Fargo cut its rating to Equal Weight but left a $374 price target — the target essentially aligns with the deal price, implying limited upside beyond the acquisition terms unless a competing bid emerges. Penumbra downgraded at Wells Fargo
• Neutral Sentiment: Market commentary and earnings-estimate revisions note strong recent volume and a large one-day surge; analysts point to momentum but caution on sustainability absent competing bids or further fundamentals. Zacks coverage of Penumbra price move
• Negative Sentiment: Needham downgraded Penumbra from Buy to Hold — a straightforward analyst reaction that could weigh on sentiment and aftermarket buying absent a higher competing bid. Penumbra downgraded at Needham
• Negative Sentiment: Multiple shareholder law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Brodsky & Smith, others) have opened investigations and class-action alerts alleging the sale price/process may be unfair — litigation or legal challenges could delay the deal, lead to renegotiation, or increase transaction costs. Kahn Swick & Foti investor alert on Penumbra sale

Wall Street Analysts Forecast Growth

PEN has been the subject of several recent research reports. Truist Financial downgraded Penumbra from a “buy” rating to a “hold” rating and lifted their price objective for the company from $370.00 to $374.00 in a report on Friday. Wells Fargo & Company restated an “equal weight” rating and issued a $374.00 price target on shares of Penumbra in a report on Thursday. Robert W. Baird reaffirmed a “neutral” rating and issued a $374.00 price target (up previously from $345.00) on shares of Penumbra in a research report on Friday. Canaccord Genuity Group lifted their price objective on shares of Penumbra from $355.00 to $359.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $355.00 price objective on shares of Penumbra in a research note on Wednesday, December 17th. Seven investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $355.88.

Penumbra Trading Up 0.1%

NYSE PEN opened at $350.93 on Friday. The company has a quick ratio of 4.18, a current ratio of 6.73 and a debt-to-equity ratio of 0.02. The firm has a market cap of $13.74 billion, a PE ratio of 83.95, a price-to-earnings-growth ratio of 2.14 and a beta of 0.71. The company has a 50 day moving average price of $303.54 and a 200 day moving average price of $269.65. Penumbra, Inc. has a 52 week low of $221.26 and a 52 week high of $352.15.

Penumbra (NYSE:PEN) last announced its earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.07. Penumbra had a net margin of 12.30% and a return on equity of 11.35%. The company had revenue of $354.69 million during the quarter, compared to the consensus estimate of $340.77 million. During the same period last year, the firm earned $0.85 earnings per share. Penumbra’s revenue was up 17.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Thomas Wilder sold 186 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $310.72, for a total transaction of $57,793.92. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Harpreet Grewal sold 186 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $312.64, for a total value of $58,151.04. Following the transaction, the director directly owned 8,230 shares in the company, valued at $2,573,027.20. This represents a 2.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 34,144 shares of company stock worth $10,260,127 over the last quarter. Company insiders own 4.20% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.